$0.38
+0.01 (+1.61%)
Open$0.38
Previous Close$0.37
Day High$0.38
Day Low$0.37
52W High$3.87
52W Low$0.33
Volume—
Avg Volume57.08M
Market Cap120.77M
P/E Ratio—
EPS$-0.69
SectorBiotechnology
Analyst Ratings
Buy
15 analysts
Price Target
+7,128.4% upside
Current
$0.38
$0.38
Target
$27.41
$27.41
$18.46
$27.41 avg
$44.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 130.28M | 95.94M | 101.30M |
| Net Income | -64,215,723 | 13.15M | 13.02M |
| Profit Margin | -49.3% | 13.7% | 12.9% |
| EBITDA | -51,187,563 | 20.01M | 19.52M |
| Free Cash Flow | — | 11.25M | 11.45M |
| Rev Growth | — | +8.6% | -0.1% |
| Debt/Equity | 6.70 | 1.02 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |